Evaluating Magnetic Resonance Spectroscopy as a Tool for Monitoring Therapeutic Response of Whole Brain Radiotherapy in a Mouse Model for Breast-to-Brain Metastasis

Woon Hyung Chae 1, Katja Niesel 1, Michael Schulz 1,2, Florian Klemm 3, Johanna A. Joyce 3, Marcus Prümmer 4, Boris Brill 1, Judith Bergs 5,6, Franz Rödel 5,6,7, Ulrich Pilatus 8 and Lisa Sevenich 1,6,7 *

1 Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany, 2 Faculty of Biological Sciences, Goethe-University, Frankfurt, Germany, 3 Department of Oncology and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland, 4 Chimaera GmbH, Erlangen, Germany, 5 Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, 6 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany, 7 Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany, 8 Institute of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

Brain metastases are the most common intracranial tumor in adults and are associated with poor patient prognosis and median survival of only a few months. Treatment options for brain metastasis patients remain limited and largely depend on surgical resection, radio- and/or chemotherapy. The development and pre-clinical testing of novel therapeutic strategies require reliable experimental models and diagnostic tools that closely mimic technologies that are used in the clinic and reflect histopathological and biochemical changes that distinguish tumor progression from therapeutic response. In this study, we sought to test the applicability of magnetic resonance (MR) spectroscopy in combination with MR imaging to closely monitor therapeutic efficacy in a breast-to-brain metastasis model. Given the importance of radiotherapy as the standard of care for the majority of brain metastases patients, we chose to monitor the post-irradiation response by magnetic resonance spectroscopy (MRS) in combination with MR imaging to closely monitor therapeutic efficacy in a breast-to-brain metastasis model. Given the importance of radiotherapy as the standard of care for the majority of brain metastases patients, we chose to monitor the post-irradiation response by magnetic resonance spectroscopy (MRS) in combination with MR imaging to closely monitor therapeutic efficacy in a breast-to-brain metastasis model.
strategies. Adapting the analytical technology in brain metastasis models to those used in clinical settings will increase the translational significance of experimental evaluation and thus contribute to the advancement of pre-clinical assessment of novel therapeutic strategies to improve treatment options for brain metastases patients.

**Keywords:** radiotherapy, brain metastases, magnetic resonance imaging, spectroscopy, metabolites, radio-response, pre-clinical models

**INTRODUCTION**

Brain metastases are the most common brain tumor in adults with an incidence of 10 per 100,000 population across all tumor types (1). Melanoma, breast- and lung cancer are the type of cancers that most frequently metastasize to the brain (2, 3). Brain metastasis is associated with poor prognosis and deteriorated quality of life due to headaches, epileptic seizures, and gradual cognitive impairment in addition to possibly advanced primary disease and dissemination to other organs (4). Improved management of primary cancers associated with prolonged patient survival has even led to an increase in the incidence of brain metastases with minimal progress in available therapeutic modalities for cerebral lesions (5, 6). Despite the known side effects of radiotherapy such as acute or delayed neurotoxicity and loss of memory function as well as radiation necrosis (7, 8), whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) still represent one of the mainstays of therapeutic intervention for brain metastases patients (7). However, detecting potential structural side effects of radiotherapy such as radiation necrosis is challenging due to its similarity to recurrent brain tumor in conventional imaging methods (9). Consequently, several studies focused on MR spectroscopy as an alternative to MRI and computer tomography (CT). MR spectroscopy provides a metabolic spectrum of a select area instead of presenting the morphology of these structures (10). Characteristic metabolic changes such as an increase in the ratio of choline (Cho) to creatinine (Cr) and Cho to N-acetylaspartate (NAA) and a concomitant decrease in NAA/Cr were proposed for recurrent malignant lesions compared to necrotic areas (11–14). Beyond the use of MR spectroscopy for discrimination of radiation necrosis and recurrent tumor, several studies suggested tumor-specific metabolite profiles for distinguishing diverse brain cancers and other non-cancerous cerebral diseases (15–18). A combination of elevated Cho, decreased Cr and NAA as well as prominent lipid/lactate levels were considered to be characteristic for brain metastases (19–22). Furthermore, high lactate levels have been found in late stage brain metastases, indicating worse patient prognosis (23). Pre-clinical research represents an important part of the effort to improve treatment option by allowing mechanistic insight into cellular and molecular drivers of tumor progression and by providing platforms to test the efficacy of novel therapeutic avenues. For this purpose, experimental tumor models and adequate technological tools are required to mimic the clinical situation as closely as possible and thus improve the quality and translational significance of preclinical research (24, 25). To date, several studies reported metabolic changes after radiotherapy in glioma cells as well as post-irradiation effects in mouse and rat models (26–29). However, there is a lack of a thorough investigation of metabolic changes in response to irradiation in experimental brain metastasis using devices specifically designed for preclinical research on small animals. The goal of this study was to investigate tumor progression and therapeutic response in an experimental syngeneic breast-to-brain metastasis model using MR imaging and MR spectroscopy. We employed a small animal 7 Tesla MR scanner adapted for MR spectroscopy and the Small Animal Radiation Research Platform (SARRP) (30) that allows for image-guided application of gamma radiation with an accuracy equivalent to clinical radiotherapy. Here, we demonstrate that MR spectroscopy in combination with MR imaging represents a valuable tool for non-invasive monitoring of parameters that reflect tumor progression or regression and provide detailed insight into the histopathological and metabolic status of brain metastases to evaluate therapeutic efficacy over time in a pre-clinical model.

**MATERIALS AND METHODS**

**Mice**

All animals were approved by the government committee (Regierungspräsidium Darmstadt, Germany) under the protocol number F123-1016 and were conducted in accordance with the requirements of the German Animal Welfare Act. C57BL6/J mice were purchased from Charles River Laboratories, Sulzfeld, Germany or bred within the animal facility at the Georg-Speyer-Haus, Frankfurt am Main.

**Cell Lines**

The brain metastatic (BrM) variant of the murine 99LN cell line was derived from a metastatic lesion in the lymph node of the MMTV; PyMT (Murine mammary tumor virus; Polyoma middle T antigen) breast cancer model and selected in vivo for brain homing capacity as previously described (31). The 99LN-BrM cell line was maintained in DMEM with 10% fetal bovine serum with 1% L-glutamine and 1% penicillin / streptomycin.

**Generation of Experimental Brain Metastases**

For brain metastases generation in immuno-competent mice, 6 × 10^4 99LN-BrM cells were inoculated into the left ventricle of 10–12-week-old female C57BL6/J mice. For tissue isolation, mice were anesthetized with 180 mg/kg ketamine and 10 mg/kg xylazine, respectively. Mice were trans-cardially perfused with PBS and 4% PFA and tissue was fixed in 4% PFA for histology.
Tissue Preparation and Immunostaining
For immunofluorescence staining, PFA fixed brain samples were sliced into 500 µm thick sections using a Vibratome VT1200S (Leica, Nussloch, Germany). Brain slices were cleared using the X-Clarity tissue clearing system (Logos Biosystem, Inc., Anyang-si, South Korea). Tissue clearance was performed at 0.6 A for 3 h using the X-Clarity electrophoretic tissue clearing solution. After tissue clearing, unspecific protein binding was blocked with 3% BSA in PBS containing 0.1% Triton-X100 and mouse-on-mouse blocking agent. Incubation of the primary antibodies rabbit anti-mouse NeuN (abcam; 1:3,000), goat anti-mouse GFAP (abcam; 1:1,000), and mouse anti-mouse γH2AX (Millipore, 1:200) was performed for 24 h at room temperature followed by incubation of fluorescently labeled secondary antibodies (Jackson Immunoresearch, 1:500) overnight at room temperature. Hoechst was used as nuclear counterstain. Samples were embedded in X-Clarity mounting media.

For immunohistochemistry, PFA fixed samples were embedded into paraffin and 5 µm sections were prepared. Formalin-fixed paraffin embedded (FFPE) samples were processed using the Leica Bond Max (Leica, Nussloch, Germany). The automated deparaffinization/rehydration, citrate-buffer-based antigen retrieval, and blocking of unspecific protein binding and endogenous peroxidase was followed by incubation with rabbit anti-mouse EpCAM (abcam; 1:1,000), rabbit anti-Il1b (abcam; 1:1,000), goat anti-GFAP (abcam; 1:1,000), rabbit anti-NeuN (abcam; 1:3,000), rabbit anti-Olig2 (1:500), and subsequent HRP-labeled secondary antibody incubation (Jackson Immunoresearch; 1:1,000) and incubation with the peroxidase substrate DAB. Hematoxylin was used as nuclear counterstain.

Microscopy and Image Analysis
Immunofluorescence staining on cleared thick sections was visualized using the Yokogawa CQ1 confocal microscope (Yokogawa, Musashino, Japan) using a 60x objective. Immunohistochemical stainings of FFPE samples were acquired by the Aperio Digital Pathology Slide scanner for gross images and a Carl Zeiss Axiolmager Z1 microscope for higher magnification. Ki67-positive proliferating cells and CC3-positive apoptotic cells were quantified using the Aperio Image Scope software as percentage of total cells in the tumor area.

Radiotherapy With the Small Animal Radiation Research Platform (SARRP)
After detection of metastatic lesions by MRI 1 day before radiotherapy (d-1) in order to determine initial values, animals were stratified into no-IR control and WBRT treatment groups. Radiotherapy was applied on d0 with the Small Animal Radiation Research Platform (SARRP, X-Strahl Ltd, Camberley, UK) (30). The SARRP is equipped with an onboard Cone Beam CT (CBCT) system for diagnostic imaging and radiation treatment process. The integrated Muriplan software allows contouring, electron density assignment, treatment planning, dose calculation, and treatment delivery. Mice were anesthetized with isoflurane (2.5%), stabilized in the prone position and imaged by performing a CBCT operating at 60 kV and 0.8 mA. CBCT images were next transferred to the Muriplan software and individual isocenters were selected for radiotherapy. Irradiation was applied as WBRT with a single dose of 10 Gy using a 10 × 10 mm collimator as 1 arc operating at 220 kV and 13 mA with 5.2 cGy sec⁻¹.

MR Imaging and Data Analysis
MR spectroscopy and MR imaging were performed using a 7 Tesla Small Animal MR Scanner (PharmaScan, Bruker, Ettlingen, Germany) with a volume coil as transmitter and a head surface coil for signal reception. Data acquisition was performed using the Paravision 6.0.1 software. For MR scans, mice were anesthetized with isoflurane (2%) and stabilized in the prone position with a tooth holder. During the MR scanning the anesthesia with ~2% of isoflurane was continued by using a built-in nosecone specially constructed for gas anesthesia. Respiration rate was monitored and kept constant at 80–100 breaths per minute continuously throughout the measurement by up- or downregulating the gas anesthesia according to the registrated respiration rate. Body temperature was maintained at 36–37°C with a built-in animal waterbed (Bruker, Ettlingen, Germany). Mice were injected intraperitoneally (i.p.) with 150 µl Gadobutrol (Gadovist, 1 mmol ml⁻¹) before the measurement. Images were acquired in coronal planes. For T2-weighted images, a localized T2-multislice Turbo rapid acquisition with relaxation enhancement (T2 TurboRARE; TE/TR = 33 ms/2,500 ms) was used while a T1-weighted RARE sequence (T1 RARE; TE/TR = 6.5 ms/1,500 ms) was applied for obtaining T1-weighted images. The following other imaging parameters were used: FOV = 20 × 20 mm, 11 slices, 0.5 mm slice thickness, acquisition matrix = 256 × 256, flip angle 90°. MR images were exported as DICOM files and analyzed in OsiriX (32). Volumetric analysis of brain metastases was performed on MR image DICOM files using the threshold-based semi-automated segmentation tool (Chimaera GmbH, Erlangen, Germany) as an aycan OsiriX plug-in (33). For quantification of contrast-enhancing lesions in T1-weighted images, the high intensity smart brush tool was used given the hyperintense appearance of tumor area compared to normal brain parenchyma. Other pathologies leading to hyperintensity in MRI, such as edema could be excluded from the quantification process by comparing the MR image with its corresponding histology. After marking the tumor region with the brush, volume in mm³ was calculated automatically by the software plug-in.

1H MR Spectroscopy and Data Analysis
Single voxel spectroscopy (SVS) was performed using the point resolved spectroscopy sequence (PRESS) with an echo time (TE) of 16.5 ms, a repetition time (TR) of 2,500 ms, spectral width of 3301.6 Hz and 2,048 points data size. 64 acquisitions were averaged in 2:40 min. Additionally, the sequence was repeated with a TE of 135 ms, TR of 2,500 ms and 256 averages (acquisition time 10:40 min) for a lactate peak inversion. A voxel of 3 × 3 ×
3 mm was placed at the brain metastases area. The target selection was based on T2-weighted MRI data from the imaging protocol. The volume of interest (VOI) was selected to contain the brain metastases area. In order to obtain best shimming results and least disturbance by the skull as well as by tissues other than the brain, only mice with tumor lesions in the central region of the brain were used, while animals with brain metastases in the olfactory bulb or cerebellum were not included. For each measurement, homogeneity after shimming, measured as the full width at half maximum (FWHM) of the water peak was below 25 Hz. MR spectroscopic data was processed using the java-based MR user interface spectroscopic analysis package (jMRUI version 5.2) (34) employing AQSES (Automated Quantification of Short time Echo MRS), a time domain quantification method with

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** MRI of brain metastasic lesions in the 99LN-BrM model. (A) Schematic depicting the selection of brain metastastic variants derived from parental cell lines through multiple rounds of in vivo selection following intra-cardiac injection. (B) Representative MR images of T1- and T2-weighted sequences with and without contrast enhancement. (C) Representative MR images and H&E stained sections for different stages of tumor progression (small, intermediate, and large BrM). Scale bar indicates 1.5 mm. (D) Representative images of brain metastasis-associated stromal reactions. Tumor cells stained for the epithelial cell marker EpCAM, astrocytes, macrophages/microglia, neurons and oligodendrocytes are detected by GFAP, Iba1, NeuN, and Olig2 expression, respectively. Scale bars indicate 100 µm.
finite impulse response (FIR) filtering, with which the residual water component could be filtered during the post-processing. Additionally, Cramer Rao lower bounds (CRLBs) of the metabolites of interest could be obtained from the quantification procedure (35). The following metabolites were included in the analysis: alanine (Ala), aspartate (Asp), ascorbate/vitamin C (Asc), glycerophosphocholine (GPC), phosphocholine (PCho), creatine (Cr), phosphocreatine (PCr), glucose (Glc), glutamine (Gln), glutamate (Glu), glutathione (GSH), glycine (Gly), myo-inositol (myo-Ins), lactate (Lac), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), phosphoethanolamine (PE), scylo-inositol (scylo-Ins) and taurine (Tau). The respective basis data sets were generated by quantum-mechanical simulation using NMR-SCOPE-B (36), which is provided in the jMRUI package. Chemical shifts and scalar coupling constants were obtained from Govindaraju et al. (37). Based on literature, the following terms were defined to determine aggregated values for metabolites that are difficult to separate from each other: tCho=GPC+PCho, tCr=PCr+Cr, tNAA=NAA+NAAG. These values as well as Lac were considered as the most relevant for this study, and ratios were calculated for tCho/tCr, tNAA/tCr, tCho/tNAA, and Lac/tCr. MR data from non-treated tumor-free controls ($n=3$), non-treated tumor controls ($n=4$), irradiated tumor-free mice ($n=3$) as well as irradiated tumor mice ($n=5$) were obtained one day prior to irradiation and on day 2, 5, 7, 9, 12, 14, 16, 19, and 21 after irradiation. Day 21 was determined as an endpoint due to the extent of the tumor, especially in untreated tumor-bearing mice, accompanied by development of symptoms including weight loss and disequilibrium.

**Data Presentation and Statistical Analysis**

Data are presented as means with standard deviation (s.d.) using GraphPad Prism Pro7. Numeric data were analyzed using two-way ANOVA and unpaired two-tailed Student’s t-test unless otherwise noted. Differences in tumor progression were calculated as area under the curve with a non-linear curve fit for tumor growth. For comparison of the post-irradiation progression of metabolites and metabolite ratios,
linear regression lines including a test for significance between the regression slopes were calculated. Baseline was corrected in all metabolites and metabolite ratios as percent deviation from the mean.

RESULTS

Magnetic Resonance Imaging of Experimental Brain Metastasis

To monitor tumor progression and radio-response in experimental brain metastasis, we used an immuno-competent mouse model for breast-to-brain metastasis (Figure 1A). In this model, the brain-homing variant of the murine breast cancer cell line 99LN was injected intra-cardially (i.c.) into C57BL6/J mice, resulting in the formation of multiple metastatic lesions in the brain parenchyma (31). MR imaging using T2- and T1-weighted sequences revealed that first metastatic lesions occur after 6–8 weeks. Small lesions were detectable as hyperintense areas in T1-weighted sequences following contrast enhancement with the gadolinium-based contrast agent Gadobutrol (Figures 1B,C). In particular, T2-weighted sequences with contrast enhancement provided information on histopathological parameters. Necrosis presented as hypointense areas, while hemorrhagic areas and edema around metastatic lesions appeared hyperintense (Figure 1C). Tumor progression could be followed for 12–15 weeks after tumor cell inoculation, a time point at which most animals developed symptoms characterized by neurological deficits including head tilts and disequilibrium. Moreover, metastatic progression led to a pronounced stromal reaction characterized by the induction of astrogliosis and recruitment and activation of tumor-associated macrophages/microglia as previously described for the 99LN-BrM model and other experimental brain metastasis models (31, 38–40). In contrast to reactive astrocytes and microglia, other brain-resident cell types

![FIGURE 3](https://example.com/figure3.png) Therapeutic response to WBRT in BrM. (A) Schematic depicting the experimental design to follow tumor progression after WBRT in BrM. (B) Representative MR images showing detection and volumetric assessment of metastatic lesions using the threshold-based semi-automated segmentation tool (Chimaera GmbH). (C) Representative MR images of tumor-bearing mice with and without WBRT at different time points. (D) Quantification of the increase in tumor volume over time in tumor-bearing no-IR control mice (n = 4) and in response to 1 × 10 Gy WBRT (n = 9) using MRI. Curves depict tumor growth of individual mice. (E) Waterfall plots depict the percent increase in tumor volume on d12 and d21 relative to d-1. *Data shown for Mouse 1 were acquired on d11. P-values were obtained using two-way ANOVA and unpaired two-sided Student’s t-test. *P < 0.05.
including neurons and oligodendrocytes were rather displaced by growing lesions (Figures 1D, 7B for gross overview), leading to a complete absence of those cell types within metastatic lesions.

**Whole Brain Radiotherapy Induces Double Strand Breaks in Brain Resident Cell Types in Tumor-Free Mice**

We chose Whole Brain Radiotherapy (WBRT) as therapeutic intervention mirroring the current clinical therapy regimen for patients with multiple metastatic lesions. WBRT was applied by the SARRP (30) as a single dose (1 × 10 Gy; 1 arc) using a 10 × 10 mm collimator to cover the area of the brain but spare extracranial regions (Figure 2A). Application of WBRT using 1 arc resulted in a focused dose distribution with nearly 100% of the relative dose reaching the target organ and only marginal scattering of radiation to extracranial regions (Figures 2B,C). Next, we evaluated effects of ionizing radiation (IR) on brain-resident cell types in non-tumor bearing mice to validate that IR delivered by the SARRP leads to induction of DNA damage. Immunofluorescence staining of Ser139 phosphorylated histone H2AX (γH2AX) confirmed that the application of 1 × 10 Gy as WBRT on healthy brain leads to DNA double strand breaks in radiosensitive neurons, while no or only low γH2AX levels were detectable in radio-resistant cell types including astrocytes (Figure 2D).

**Whole Brain Radiotherapy Blocks Tumor Progression in Brain Metastasis-Bearing Mice**

After we confirmed that 1 × 10 Gy WBRT leads to DNA damage in radio-sensitive brain-resident cell types (i.e., neurons), we irradiated brain metastases-bearing animals and followed the effects of WBRT over 21 days with MRI measurements every 2–3 days (Figure 3A). Volumetric analysis was performed using a threshold-based semi-automated segmentation tool (33) to detect contrast-enhancing lesions in T1 (Figure 3B). Untreated control mice (no-IR Ctrl) showed continuous tumor growth leading to an average increase in tumor volume of 816% ± 256 at d12 (n = 4). In contrast, WBRT led to significant reduction in the growth kinetic leading to an average increase in tumor volume of 122% ± 22 at d12 after treatment (n = 5) (Figures 3C–E). After the initial phase of growth stasis, tumors rebound around d16 after WBRT. To further confirm the effect of IR on the growth kinetic in the 99LN-BrM model, we compared the tumor progression and radio-response in an independent cohort with measurements once per week until d21 and observed similar effect on tumor growth as in the cohort used for spectroscopic analysis (Supplementary Figure 1A). Tumor progression in the independent cohort (n = 17 and 11 for untreated and treated mice, respectively) was followed until the animals developed symptoms due to brain metastasis. Survival analysis revealed that the initial effects on tumor growth do not translate into a significantly prolonged overall survival of the mice (Supplementary Figure 1B).

**Brain Metastasis Progression and Radio-Response Are Characterized by Distinct Metabolic Profiles**

We next sought to assess metabolic changes during brain metastasis growth to determine metabolite concentrations at different stages of tumor progression (Figures 4, 5). We measured concentrations of creatine (tCr), choline (tCho), and N-acetylaspartate (tNAA) as indicators for energy metabolism, membrane turnover and neuronal dysfunction or displacement, respectively (15, 41). Additionally, we measured lactate (Lac) employing the lactate peak inversion at long TE for distinction between lactate signals and macromolecules (Figure 4B). Cramer Rao Lower Bounds (CRLBs) of the metabolites of interest were in mean 16.97 and 8.8% of...
signal intensities of each metabolite in measurements with short and long echo time, respectively, indicating a high reliability of the values obtained (Supplementary Figure 2). First, we measured metabolite concentrations in tumor-free control mice (n = 3) that did not receive WBRT to determine variability in metabolite levels in normal brain over time in comparison to tumor-free mice that received WBRT (n = 3) (Supplementary Figure 3). Our data confirmed that metabolite levels in untreated tumor-free mice remain stable over time with only minor variation of metabolite levels at different time points (Supplementary Figures 3A,B). Similar effects were observed in non-tumor bearing mice that received 1 × 10 Gy WBRT (n = 3) (Supplementary Figures 3A,B) indicating that irradiation does not induce major changes in cellular composition or metabolic activity in brain-resident cell types with the exception of tCho that showed a marginal increase in irradiated non-tumor bearing mice in the short TE measurements (Supplementary Figures 3A,B). In contrast, brain metastasis led to a significant decrease in tCr and tNAA concentrations, while an enhancement of lactate levels could be observed in
this model (Figures 5A,B, Table 1). Despite of tumor growth, tCho concentrations remained stable over time. Calculation of ratios between different metabolites, in particular tCho/tCr, tCho/tNAA, tNAA/tCr, and Lac/tCr is used in the clinic to obtain relative metabolite concentrations based on an internal reference. tCho/tCr and tCho/tNAA additionally represent cellular density (15). Our data indicate that tumor progression is represented by the ratio of tCho/tCr and tCho/tNAA as well as by Lac/tCr in the 99LN-BrM model (Figures 5A,B, Table 1). Importantly, comparison of baseline-corrected metabolite levels as well as ratios revealed that the loss of tCr and tNAA and increase in Lac in WBRT-treated animals (n = 3) occurred at a slower rate than in untreated tumor-bearing mice (n = 4) leading to changes in metabolite levels over time close to levels found in non-tumor bearing mice during the measurement period (Figures 5A,B, Supplementary Figures 3A,B). However, metabolite levels in tumors at d-1 and WBRT end-stage tumors showed significant differences of tCr and tNAA levels compared to non-tumor-bearing brains (Figures 6A,B). Metabolic changes detected by MR spectroscopy highly correlated with volumetric measurements of tumor progression in non-treated animals (Figures 6C,D). Interestingly, in irradiated animals the correlation between volumetric and metabolic changes was less pronounced suggesting that spectroscopy detects radio-responses that are not fully captured by conventional volumetric MR imaging (Figures 6C,D). Thus, the combination of MR imaging and spectroscopy provides more comprehensive insight into histopathological and metabolic parameter for reliable analysis of therapy responses in experimental brain metastasis than conventional imaging techniques alone.

**Assessment of Histopathological Parameters After Whole Brain Radiotherapy**

To validate changes in histopathological parameters detected by MR imaging and spectroscopy, we performed histological assessment of the rate of proliferation and apoptosis as well as the presence of neurons within the analyzed tumor area at the trial endpoint. Histological detection of neurons confirmed that brain metastatic progression leads to displacement of NeuN+ cells indicating that the decrease in tNAA levels can be attributed to the reduction in the number of neurons within the tumor lesions while the tumor area within the voxel increased (Figures 7A,B). Displacement of normal brain tissue occurred at a slower rate in response to WBRT leading to higher levels of tCr and tNAA. Analysis of the proliferation rate revealed a significantly higher percentage of Ki67+ cells in rebound tumors after IR compared to untreated animals at the trial endpoint with a trend toward a higher percentage of CC3+ apoptotic cells in irradiated tumors. Consequently, the ratio of Ki67+ to CC3+ cells was similar in both groups in end-stage tumors (Figures 7B,C). Moreover, histological assessment revealed the presence of necrotic areas in irradiated and control tumors at trial end point indicating that tumor progression itself leads to necrosis. Comparison of tumors with similar sizes in both groups showed a more dense growth pattern in the control tumors indicating that radiation enhances the induction of necrosis (Supplementary Figure 4) but is not the only cause for necrosis at trial endpoint.

In sum, we demonstrated that MR imaging in combination with MR spectroscopy represents a valuable tool for non-invasive, longitudinal measurement of experimental brain metastasis. Assessment of histopathological and metabolic parameter that are characteristic for progressing vs. regressing tumors are important measures to evaluate therapeutic efficacy over time.

**DISCUSSION**

Recent technological and conceptual advances provide unprecedented opportunities to identify and study drivers of brain metastasis with the ultimate goal to develop novel treatment options to improve prognosis and quality of life for brain metastases patients. The development of novel therapeutic avenues (5, 42, 43) requires thorough preclinical testing of intervention strategies in experimental models that closely mimic the clinical situation. Closing the technological gap between clinical and preclinical instrumentation and employing diagnostic tools used for patients will improve the translational significance of preclinical research (24, 30, 44). To test the applicability of implementing MR spectroscopy into the monitoring routine in the pre-clinical setting, we chose radiotherapy as the therapeutic intervention strategy. Despite the debate on WBRT concerning its long-term side effects and failure to prolong overall survival, it still remains part of
current clinical therapy regimens for brain metastasis patients with short life expectancy. Data obtained by MR spectroscopy revealed a pronounced reduction of total NAA and total creatine as well as a significant increase in lactate levels in untreated 99LN-BrM-bearing mice, while total choline levels remained stable over time. We observed a strong correlation between tumor growth and reduction of tCr and tNAA as well as increase in Lac. Reduction of tNAA levels during tumor growth is indicative for the loss of neuronal structures or function (41) and gradual loss of tCr and tNAA in progressing brain tumors can at least in part be attributed to the displacement of normal brain structures by highly proliferating tumor cells. Hence, the partial volume effect is expected to be more pronounced in brain metastases with expanding growth pattern compared to brain tumors with infiltrative growth such as high-grade glioblastoma (16–18). Indeed, while NAA levels are known to be decreased in primary brain tumors such as glioblastoma and astrocytoma, it has been shown to be almost completely absent in brain metastases (45–48). In line with these findings, we found that brain metastases progression in the 99LN-BrM model leads to displacement of neurons by the growing tumor with no NeuN+ cells being detectable within the tumor bulk. At early stages of tumor progression, the volume of interest contained small metastatic lesions and a considerable amount of adjacent healthy brain tissue. The ratio of tumor area to healthy brain tissue within the voxel changed over time with less normal parenchyma contributing to the spectrum at advanced disease stages.

Creatine is considered as a marker for cellular aerobic energy metabolism given its role in ATP synthesis mediated by the creatine kinase (49). Creatine levels have been shown to be stable under different conditions (50, 51), while displaying differences in distinct brain regions (52). It was demonstrated that creatine levels are significantly lower in non-neuroectodermal tumors, i.e., in brain metastases compared to neuroectodermal tumors such as glioblastoma (11, 48, 53, 54). For example, Ishimaru et al. described a complete absence of creatine in brain metastases (16), which supports our interpretation of a partial volume effect also in creatine levels due to the expanding growth of brain metastases. Accordingly, tNAA/tCr, which is often calculated under the premise of stable creatine, is not significantly reduced over time in experimental brain metastasis. Lactate, resonating at 1.33 ppm, indicates enhanced anaerobic metabolism and is associated with brain tumor, cerebral ischemia, stroke and mitochondrial diseases, such as Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) or Myoclonic Epilepsy with Ragged Red Fibers (MERRF) (23, 55–58). Several studies suggested increased lactate concentrations in higher grades of brain cancer as well as in rapidly growing tumors.
We observed increasing levels of lactate during tumor progression in untreated mice, while it remained stable in irradiated tumor-bearing and wild-type mice. This indicates that suppression of tumor growth in response to irradiation in 99LN-BrM mice results in lower cell density and thus might lead to less production of lactic acid over time. Lactate has also been described to be enhanced in regions with subacute radiation necrosis in addition to reduced NAA levels (26, 61, 62). However, a detection of radiation necrosis in terms of increased lactate levels or reduced NAA after WBRT could not be confirmed in irradiated wild-type controls in this study. Supposably, the observation time after the irradiation was too short to detect any long-term side effects of the irradiation. It is also possible that the irradiation dose was not sufficient to cause pronounced radiation necrosis as also evidenced by histopathological assessment.

Surprisingly, we did not observe elevated choline levels in brain metastases compared to normal brain tissue and during tumor progression. This finding is inconsistent to previous findings that described significant increase of choline in all analyzed brain tumors (61, 63–65) and other solid cancer types such as breast cancer (66–68) compared to adjacent healthy tissue. Total choline compounds, consisting of phosphocholine, glycerophosphocholine, and free choline, are considered as a surrogate marker for membrane integrity and turnover (41). Moreover, an increase in total choline and a switch from glycerophosphocholine to phosphocholine has been described in malignant lesions (69–71). However, high choline concentration was also described in normal glial cells (72). It is possible that in the 99LN-BrM model, choline levels in tumor cells and glial cells are similar. Consequently, a partial volume effect by displacing normal tissue would not be detectable in changes in choline levels. Stable choline levels in tumor-bearing mice over time might also be explained by the involvement of necrotic and cystic areas with decreased choline levels (63,
Given the instrument configuration and the small size of brain metastases in mouse models, it is technically challenging to target only viable tumor areas in the MR spectroscopy measurements due to tumor heterogeneity. Hence, a possible increase of choline levels in viable tumor areas with high proliferation rates might be masked by the presence of dying cells in necrotic areas. Measurements in more homogeneous tumor areas would facilitate the interpretation of acquired spectra. However, selecting a smaller voxel size significantly increases measurement time and requires additional techniques such MR spectroscopic imaging (73).

Given the differences in the correlation coefficient in the no-IR Ctrl and WBRT treatment groups with respect to volumetric and metabolic measurements, our data on experimental brain metastasis indicate that MR spectroscopy detects therapeutic responses that are not fully captured by MR imaging. In future studies, we plan to include MR spectroscopy in our preclinical trials as an additional non-invasive diagnostic tool to gain insight into therapeutic responses over time to evaluate treatment efficacy of different novel intervention strategies that hopefully provide strong scientific rationale for improved therapeutic avenues for brain metastasis patients.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/Supplementary Material.

ETHICS STATEMENT

All animal studies were approved by the government committee (Regierungspräsidium Darmstadt, Germany) under the protocol number F123-1016 and were conducted in accordance with the requirements of the German Animal Welfare Act. C57BL6/J mice were purchased from Charles River Laboratories, Sulzfeld, Germany or bred within the animal facility at the Georg-Speyer-Haus, Frankfurt am Main.

AUTHOR CONTRIBUTIONS

WC and LS designed the project. WC, KN, MS, JB, FR, UP, and LS performed experiments and analyzed data. MP, FK, and JJ provided material. FR, BB, and UP advised on radiotherapy and MR spectroscopy. WC and LS wrote the manuscript. All authors read and approved the manuscript.

FUNDING

Work in the lab of LS was supported by grants from the German Cancer Aid (Max-Eder Junior Group Leader Program 70111752), the German Research Foundation (SE2234/3-1), the LOEWE Center Frankfurt Cancer Institute (FCI), and the German Cancer Consortium (DKTK partner site Frankfurt/Mainz) as well as by institutional funds from the Georg-Speyer-Haus. The Georg-Speyer-Haus was funded jointly by the German Federal Ministry of Health and the Ministry of Higher Education, Research and the Arts of the State of Hesse (HMWK).

ACKNOWLEDGMENTS

We would like to thank members of the animal and histology facility for excellent technical support, in particular Petra Dinse for the preparation and staining of histological sections. We are grateful to Dr. Schmid and Prof. Pichler, Werner Siemens Imaging Center, Tübingen for their help on establishing protocols for MR spectroscopy on the Small Animal MRI. We would like to thank Julius Oppermann, Marco Loh, and Tijana Alekseeva for their assistance in applying radiotherapy and performing MR imaging. We thank Dr. Ursula Dietrich for reading the manuscript and insightful discussion. JB gratefully acknowledges funding from the German Research Foundation (GRK2260, BIOQIC).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.01324/full#supplementary-material

REFERENCES

1. Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int. (2013) 4:S192–202. doi: 10.4103/2152-7806.111296

2. Witzel I, Oliveira-Ferrer I, Pantel K, Muller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. (2016) 18:8. doi: 10.1186/s13058-015-0665-1
43. Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, et al. The evolving landscape of brain metastasis. *Trends Cancer*. (2018) 4:176–96. doi: 10.1016/j.trecan.2018.01.003

44. Nowosielski M, Radbruch A. The emerging role of advanced neuroimaging techniques for brain metastases. *Chin Clin Oncol*. (2015) 4:23. doi: 10.3978/j.issn.2304-3865.2015.05.04

45. Delorme S, Weber MA. Applications of MRS in the evaluation of focal malignant brain lesions. *Cancer Imaging*. (2006) 6:95–9. doi: 10.1102/1470-7330.2006.0015

46. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. *Magn Reson Med*. (2003) 49:223–32. doi: 10.1002/mrm.10367

47. Poptani H, Gupta RK, Roy R, Pandey R, Iain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. *AJNR Am J Neuroradiol*. (1995) 16:1593–603.

48. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vivo proton magnetic resonance spectroscopy. *NMR Biomed*. (1997) 10:2–12.

49. Miller BL. A review of chemical issues in 1H MRS spectroscopy: N-acetyl-L-aspartate, creatine and choline. *NMR Biomed*. (1991) 4:47–52. doi: 10.1002/nbm.1820040103

50. Soreni N, Noseworthy MD, Cormier T, Oakden WK, Bells S, Schachar R. Intracellular variability of striatal (1)H-MRS brain metabolite measurements at 3 T. *Magn Reson Imaging*. (2006) 24:187–94. doi: 10.1016/j.mri.2005.10.027

51. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. *J Magn Res Imaging*. (1999) 9:711–6.

52. Minati L, Aquino D, Bruzzone MG, Erbetta A. Quantitation of normal metabolite concentrations in six brain regions by in-vivo H-MR spectroscopy. *J Med Phys*. (2010) 35:154–63. doi: 10.4103/0971-6203.620128

53. Lawry OH, Berger SI, Chi MM, Carter JG, Blackshaw A, Outlaw W. Diversity of metabolic patterns in human brain tumors. 1. High energy phosphate compounds and basic composition. *J Neurochem*. (1977) 29:959–77. doi: 10.1111/j.1471-4159.1977.tb06500.x

54. Moller-Hartmann W, Herminghaus S, Kring T, Pilatus U, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. *Neuroradiology*. (2002) 44:371–81. doi: 10.1007/s00234-001-0760-0

55. Barkovich AJ, Good WV, Koch TK, Berg BO. Mitochondrial disorders: analysis of their clinical and imaging characteristics. *AJNR Am J Neuroradiol*. (1993) 14:1119–37.

56. Lee DW, Chung H, Lee SP, Choi KW, Yeo HT, Kim OD, et al. Brain tumors in which lactate and lipid have been detected: a proton magnetic resonance spectroscopy study. *J Korean Neurosurg Soc*. (1998) 27:5–14.

57. Arnold DL, Shoubridge EA, Villeneuve JG, Feindel W. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. *NMR Biomed*. (1990) 3:184–9. doi: 10.1002/nbm.1990030407

58. Fulham MJ, Bizzz A, Dietz MJ, Shih HH, Raman R, Sobering GS, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. *Radiology*. (1992) 185:675–86. doi: 10.1148/radiology.185.3.1438744

59. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotis ED, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. *J Neurosurg*. (1996) 84:449–58. doi: 10.3171/jns.1996.84.3.0449

60. Chan KC, Khong PL, Cheung MM, Wang S, Cai KX, Wux EY. MRI of late microstructural and metabolic alterations in radiation-induced brain injuries. *J Magn Res Imaging*. (2009) 29:1013–20. doi: 10.1002/jmri.21736

61. Falini A, Bizzzz M, Magnani G, Pero G, Gambini A, Benedetti B, et al. A whole brain MR spectroscopy study from patients with Alzheimer’s disease and mild cognitive impairment. *Neuroimage*. (2005) 26:1159–63. doi: 10.1016/j.neuroimage.2005.03.005

62. Telleschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. *J Neurosurg*. (1997) 87:516–24. doi: 10.3171/jns.1997.87.4.0516

63. Tien LD, Lai PH, Smith JS, Lazeys F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. *AJR Am J Roentgenol*. (1996) 167:201–9. doi: 10.2214/ajr.167.1.8659372

64. Aboagy EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. *Cancer Res*. (1999) 59:80–4.

65. Baik HM, Su MY, Yu H, Mehta R, Niculesu O. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. *MAGMA*. (2006) 19:96–104. doi: 10.1007/s10334-006-0032-4

66. Jagannathan NR, Kumar M, Seenu V, Cosic O, Dwivedi SN, Julka PK, et al. Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neo/adjuvant chemotherapy in locally advanced breast cancer. *Br J Cancer*. (2001) 84:1016–22. doi: 10.1054/bjoc.2000.1711

67. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. *Mol Pharm*. (2006) 3:496–506. doi: 10.1021/mp050067e

68. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. *Nat Rev Cancer*. (2011) 11:835–48. doi: 10.1038/nrc3162

69. Herminghaus S, Pilatus U, Muller-Hartmann W, Raab P, Lanfermann H, Scholte W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. *NMR Biomed*. (2002) 15:385–92. doi: 10.1002/nbm.793

70. Barker PB, Bonekamp D, Reddy G, Smith M. Quantitation of NAA in the brain by magnetic resonance spectroscopy. *Adv Exp Med Biol*. (2006) 576:183–97; discussion 361–3. doi: 10.1007/978-0-387-30172-0_13

71. Barisang O, Sepehrband F, Ma S, Jann K, Cabeen R, Wang DJ, et al. Clinical 7T MRI: are we there yet? A review about magnetic resonance imaging at ultra-high field. *Br J Radiol*. (2019) 92:20180492. doi: 10.1259/bjr.20180492

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Chae, Nisel, Schulz, Klemm, Joyce, Priammer, Brill, Bergs, Rödel, Pilatus and Sevenich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.